Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus
10.4093/jkd.2019.20.3.142
- Author:
Seung Hyun KO
1
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. kosh@catholic.ac.kr
- Publication Type:Practice Guideline
- Keywords:
Diabetes mellitus;
Type 2;
Hypoglycemic agents;
Practice guideline
- MeSH:
Alcoholism;
Diabetes Mellitus;
Diabetes Mellitus, Type 2;
Dipeptidyl Peptidase 4;
Glucagon-Like Peptide 1;
Humans;
Hypoglycemic Agents;
Insulin;
Life Style;
Metformin;
Motor Activity;
Nutrition Therapy;
Risk Factors;
Smoking Cessation;
Thiazolidinediones
- From:Journal of Korean Diabetes
2019;20(3):142-148
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
For patients with newly diagnosed type 2 diabetes mellitus (T2DM), lifestyle modifications including medical nutrition therapy, weight control, physical activity, smoking cessation, and avoidance of alcohol abuse should be initiated. Metformin must be considered as the first-line oral glucose-lowering therapy, but other drugs such as dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, thiazolidinediones, glucagon-like peptide 1 receptor agonists, sulfonylureas, glinides, α-glucosidase inhibitors, and insulin can be considered based on patient circumstances. If the initial HbA1c level of a patient is ≥ 7.5% or the HbA1c target is not achieved within three months of initiating monotherapy, dual combination therapy can be considered. If the HbA1c target is not achieved within 3 months of initiating dual therapy, a third agent with a complementary mechanism of action can be added for triple combination therapy. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of SGLT-2 inhibitors in T2DM patients with cardiovascular risk factors have been incorporated into the updated recommendations.
